Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mesoblast Completes Institutional Allocation

December 4, 2023

Entitlement Offer and Placement Investor Presentation

December 4, 2023

MSB Launches Entitlement Offer and Placement

December 4, 2023

Update on BLA for Graft Versus Host Disease

August 4, 2023

MSB Reports Q3 Financial Results and Operational Highlights

May 25, 2023

Third Quarter Financial Results on Form 6-K

May 25, 2023

Reinstatement to Official Quotation

April 26, 2023

Mesoblast Completes Private Placement

April 26, 2023

Voluntary Suspension

April 23, 2023

FDA Accepts Mesoblasts BLA Resubmission for Remestemcel-L

March 7, 2023

DREAM HF Trial Published in JACC

February 27, 2023

Half Yearly Report and Accounts

February 27, 2023

Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD

January 31, 2023

Extension of Undrawn US$30 million Facility

December 22, 2022

Long-Term Survival for Acute GvHD Treatment with Remestemcel

November 22, 2022

MSB Q1 Financial Results and Operational Highlights

November 22, 2022

First Quarter Financial Results on Form 6-K

November 22, 2022

Submits New Information to FDA IND File for SR-aGVHD

October 2, 2022

MSB Annual Financial Results and Operational Highlights

August 30, 2022

Preliminary Final Report

August 30, 2022

US$45 Million Private Placement to Major Shareholders

August 9, 2022

Reinstatement to Quotation

August 9, 2022

Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE

July 19, 2022

Third Quarter Results Presentation

May 31, 2022

MSB Q3 Financial Results and Operational Highlights

May 31, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Second Quarter Results Presentation

February 24, 2022

Ulcerative Colitis & Crohns Results Presented at ECCO

February 20, 2022

Appendix 4C Quarterly Activity Report

January 30, 2022

FDAs OTAT Agrees to Primary Endpoint for Back Pain

December 15, 2021

Update on Novartis Agreement

December 13, 2021

MSB and Oaktree Conclude Refinancing of Senior Debt Facility

November 21, 2021

AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes

November 14, 2021

MSB Annual Financial Results and Operational Progress

August 30, 2021

Mesoblast Update on Chronic Low Back Pain Program

June 30, 2021

MSB Reports Q3 Financial Results and Operational Highlight

June 2, 2021

COVID ARDS Trial Topline 60-Day Results

April 29, 2021

Mesoblast Raises US$110M Led By US Strategic Investor Group

March 1, 2021

Mesoblast Phase 3 Chronic Low Back Pain Results

February 10, 2021

Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF

January 11, 2021

Mesoblast Update on COVID-19 ARDS Trial

December 17, 2020

Trading halt

December 16, 2020

Mesoblast Phase 3 Chronic Heart Failure Results

December 14, 2020

Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS

December 1, 2020

Novartis and Mesoblast Remestemcel-L Collaboration

November 19, 2020

First Quarter Results Presentation

November 19, 2020

DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial

November 10, 2020

COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C

October 28, 2020

MSB Wins Fierce Biotech Innovation Award for Remestemcel-L

September 15, 2020

DSMB Recommends Continuation of Phase 3 COVID-19 Trial

September 4, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.